Deroy & Devereaux Private Investment Counsel Inc. Has $21.57 Million Stake in Becton Dickinson and Co (BDX)

Deroy & Devereaux Private Investment Counsel Inc. lifted its position in Becton Dickinson and Co (NYSE:BDX) by 1.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 90,049 shares of the medical instruments supplier’s stock after acquiring an additional 1,073 shares during the period. Becton Dickinson and comprises approximately 2.2% of Deroy & Devereaux Private Investment Counsel Inc.’s holdings, making the stock its 7th largest position. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Becton Dickinson and were worth $21,572,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. MUFG Securities EMEA plc grew its position in Becton Dickinson and by 109.6% during the second quarter. MUFG Securities EMEA plc now owns 115,299 shares of the medical instruments supplier’s stock valued at $27,621,000 after purchasing an additional 60,299 shares in the last quarter. Dana Investment Advisors Inc. grew its position in Becton Dickinson and by 21.8% during the second quarter. Dana Investment Advisors Inc. now owns 38,362 shares of the medical instruments supplier’s stock valued at $9,190,000 after purchasing an additional 6,871 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Becton Dickinson and by 103.7% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 58,135 shares of the medical instruments supplier’s stock valued at $13,927,000 after purchasing an additional 29,600 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in Becton Dickinson and by 1.9% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 884,065 shares of the medical instruments supplier’s stock valued at $211,787,000 after purchasing an additional 16,246 shares in the last quarter. Finally, UMB Bank N A MO grew its position in Becton Dickinson and by 1.9% during the second quarter. UMB Bank N A MO now owns 92,937 shares of the medical instruments supplier’s stock valued at $22,264,000 after purchasing an additional 1,773 shares in the last quarter. 84.16% of the stock is currently owned by institutional investors and hedge funds.

Becton Dickinson and traded down $9.83, reaching $240.17, during trading on Thursday, according to Marketbeat.com. The company’s stock had a trading volume of 21,603 shares, compared to its average volume of 798,638. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $66.90 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.74 and a beta of 1.13. Becton Dickinson and Co has a 1-year low of $191.53 and a 1-year high of $252.74.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.86 by $0.05. The firm had revenue of $4.28 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a negative net margin of 0.46% and a positive return on equity of 14.27%. The company’s revenue was up 41.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 earnings per share. equities analysts anticipate that Becton Dickinson and Co will post 10.99 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 7th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 31.65%.

BDX has been the topic of a number of research analyst reports. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Citigroup raised shares of Becton Dickinson and from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $237.00 to $251.00 in a research report on Tuesday, April 10th. Finally, JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a research report on Thursday, June 21st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Becton Dickinson and presently has a consensus rating of “Buy” and a consensus price target of $240.88.

In other Becton Dickinson and news, insider Alexandre Conroy sold 20,128 shares of Becton Dickinson and stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $228.74, for a total value of $4,604,078.72. Following the completion of the sale, the insider now directly owns 35,583 shares in the company, valued at $8,139,255.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nabil Shabshab sold 10,209 shares of Becton Dickinson and stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $226.10, for a total transaction of $2,308,254.90. Following the completion of the sale, the executive vice president now owns 12,476 shares of the company’s stock, valued at $2,820,823.60. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Read More: Earnings Per Share (EPS)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply